Oncology

Experimental Hematology

Francesc Bosch

Researchers
Pere Barba Suñol, David Beneitez Pastor, Mercedes Gironella Mesa, Andrés López Hernández, Laura López Andreoni, Ana Marin Niebla, Isabel Massagué Ferrer, Carlos Palacio Garcia, Verónica Pons Escoll, Esther Sancho Ponce, Amparo Santamaría Ortiz, David Valcarcel Ferreiras, Maria Teresa Vallespi Sole, Bárbara Tazón Vega

Researchers in training
Noelia Purroy Zuriguel, Isabel Jiménez, Lidia Martínez

Nursing, Technical, and Administrative Staff
Elisenda Alonso Arias, Júlia Carabia Juberó, Isabel Jiménez Bernal, Mª Julia Montoro Gómez, Andrea Moral Santamaria, Mireia Olive Noguer, Oriol Olive Noguer, Pável Eduardo Olivera Sumire, Bárbara Tazón Vega

SUMMARY

During 2014 we have identified a new therapeutic target for chronic lymphocytic leukemia (CLL) that is specifically aimed at the proliferative and chemoresistant compartment. We have also thoroughly defined an ex vivo co-culture system that mimics the favorable microenvironment found in vivo in CLL. Using this system we are currently conducting pre-clinical studies of new drugs for the treatment of patients with CLL that will shortly move into clinical trials. Regarding the study of primary central nervous system lymphoma, we have established an in vivo orthotropic model using both cell lines and primary cells from patients that we will shortly use to test new therapeutic options. We are also identifying new targets in this rare but fatal disease by the deep molecular analysis of biobanked biopsies. Finally, we are also studying new potential therapeutic options in acute myeloid leukemia, both pre-clinical and in early phase clinical trials.

PUBLICATIONS

Total 28.
Impact Factor 180.893
Average I.F. 6.46

  • Byrd JC1, Brown JR, O’Brien S, Barrientos JC, Kay NE, Reddy NM, Coutre S, Tam CS, Mulligan SP, Jaeger U, Devereux S, Barr PM, Furman RR, Kipps TJ,Cymbalista F, Pocock C, Thornton P, Caligaris-Cappio F, Robak T, Delgado J, Schuster SJ, Montillo M, Schuh A, de Vos S, Gill D, Bloor A, Dearden C, Moreno C, Jones JJ, Chu AD, Fardis M, McGreivy J, Clow F, James DF, Hillmen P; RESONATE Investigators.Byrd J, Brown J, O’Brien S, Barrientos J, Kay N, Reddy N, Hillmen P, Coutre S, Tam C, Mulligan S, Jaeger U, Devereux S, Barr P, Furman R, Kipps T, Cymbalista F, Pocock C, Thornton P, Caligaris-Cappio F, Robak T, Delgado J, Schuster S, Montillo M, Schuh A, de Vos S, Gill D, Bloor A,Dearden C, Moreno C, Jones J, Pagel J, Frank R, Cull G, Etienne G, Semenzato G, Fegan C, Fox C, Hamblin M, Walewska R, Pettitt A, Bannerji R,Williams M, Tournhilac O, Troussard X, De Guibert S, Hellmann A, Marco JA, Duncombe A, Hermann RC, Ludwig H, Burgstaller S, Linkesch W,Feugier P, Mahe B, Santoro A, Marasca R, Abrisqueta P, O’Dwyer M, Schiffer C, Ahmed M, Miranda E, Greil R, Aurran-Schlenitz T, Genet P, Roca JR, Martínez JF, Vandenberghe E. Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia. N Engl J Med. 2014 Jul 17;371(3):213-23. doi: 10.1056/NEJMoa1400376. Epub 2014 May 31. PMID: 24881631
  • Barba et al, Combination of the hematopoietic cell transplantation comorbidity index and the European group for blood and marrow transplantation score allows a better stratification of high-risk patients undergoing reduced-toxicity allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transplant. 2014 Jan;20(1):66-72
  • Purroy et al, Targeting the proliferative and chemoresistant compartment in chronic lymphocytic leukemia by inhibiting survivin protein. Leukemia. 2014 Oct;28(10):1993-2004.
  • Purroy et al, Co-culture of primary CLL cells with bone marrow mesenchymal cells, CD40 ligand and CpG ODN promotes proliferation of chemoresistant CLL cells phenotypically comparable to those proliferating in vivo. Oncotarget. 2014 Dec 3. [Epub ahead of print]
  • Purroy et al, Long-term follow-up of dose-adjusted EPOCH plus rituximab (DA-EPOCH-R) in untreated patients with poor prognosis large B-cell lymphoma. A phase II study conducted by the Spanish PETHEMA Group. Br J Haematol. 2014 Dec 18. doi: 10.1111/bjh.13273. [Epub ahead of print]

 

View all the publications

MAIN RESEARCH PROJECTS

Project: Nuevas opciones terapéuticas para el tratamiento de los linfomas cerebrales primarios: terapias dirigidas hacia vías de señalización desreguladas usando modelos in vivo
Funding agency: Fondo de Investigación Sanitaria
PI: Crespo Maull, Marta

Project: Patogènesi i noves dianes moleculars en síndromes limfoproliferatives B
Funding agency: Ministerio de Economía y Competitividad
PI: Crespo Maull, Marta

Project: ZAP-70 en la regulación de la interacción de las células de la leucemia linfática crónica en el microambiente
Funding agency: Fondo de Investigación Sanitaria
PI: Bosch Albareda, Francesc

Project: Desarrollos farmacéuticos en cánceres hematológicos catalogados como enfermedades raras mediante aproximaciones basadas en apoptosis
Funding agency: Ministerio de Economía y Competitividad
PI: Bosch Albareda, Francesc

Project: Estudiio fase II prospectivo, abierto, multicéntrico de Gemcitabina y Oxaliplatino + Rituximab en pacientes con linfomas agresivos (difuso de células grandes B y del manto) en recaída o resistencia no subsidiarios de ser sometidos a quimioterapia intensa
Funding agency: Fondo de Investigación Sanitaria
PI: López Hernández, Andrés

 

View all the research projects